Hospitalization for Pneumonia Linked to Risk for CVD

Nearly one-quarter of hospitalized adults aged 50 years and older with RSV experienced an acute cardiac event, according to results of a new study.

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Pfizer plans to submit the phase 3 MONeT data to regulatory bodies in support of an expanded label for Abrysvo to include adults aged 18 to 59, the company said.

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

The study looked at the impact over 3 years but found that most of the averted burden, including more than 8000 fewer deaths, occur in the first year after vaccination.

The novel 21-valent pneumococcal vaccine remains on track for the FDA PDUFA date of June 17, 2024; Merck adds this new data to the body of positive evidence.